Form 4 for ATYR aTYR PHARMA INC
Accepted 2023-04-28 00:00:00 ET · period of report 2023-04-26 · accession 0001209191-23-026069 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-04-28 | 2023-04-26 | ATYR | CLARKE JOHN K | Dir | M - OptEx | — | +6,000 | 19.8K | +43% | — |
| D | 2023-04-28 | 2023-04-26 | ATYR | CLARKE JOHN K | Dir | M - OptEx | $0.00 | -6,000 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-04-26 | M | A | 6,000 | — | 19,797 | D | — | — | (F2) RSUs convert into common stock on a one-for-one basis. (F3) Includes 6,305 shares received as a pro-rata distribution on September 28, 2021 (the "Liquidating Distribution") from CHP II, L.P., in which the Reporting Person is a managing partner. In prior reports, the reporting person reported beneficial ownership of 108,083 shares of aTyr Pharma common stock held by CHP II, L.P., which are no longer held as of September 28, 2021 due to the Liquidating Distribution. |
| 2 | Derivative | Restricted Stock Unit | 2023-04-26 | M | D | 6,000 | $0.00 | 0 | D | — · — to — | 0 Common Stock | (F2) RSUs convert into common stock on a one-for-one basis. (F4) The RSUs fully vested one year from the grant date which was April 26, 2022. |